Overview

Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance

Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic hepatitis C virus (HCV).
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kaohsiung Veterans General Hospital.
Treatments:
Interferon-alpha
Interferons
Metformin
Ribavirin
Criteria
Inclusion Criteria:

- HCV RNA (+) and ALT > 40 U/L

- Compensated liver

- HOMA-IR > 2

Exclusion Criteria:

- neutrophil <1500/mm3

- male: Hb < 13 g/dl, female: Hb < 12 g/dl

- platelet < 80,000 /mm3

- Cr > 2.5 mg/dl

- Alcohol use > 20 gm per day

- uncontrolled depression, thyroid disease, autoimmune disease

- Pregnancy

- Hepatocellular carcinoma

- allergy to interferon or ribavirin

- Diabetes

- HBV/HIV co-infection